-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
GSK-A1
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1416334-69-4.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1416334-69-4 |
| Description | GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research. |
Product Information
| Synonyms | GSK-A1|1416334-69-4|5-[2-amino-3-(4-morpholin-4-ylphenyl)benzimidazol-5-yl]-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide|5-{2-amino-1-[4-(morpholin-4-yl)phenyl]-1H-benzimidazol-6-yl}-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide|PI4KA inhibitor-A1|A1;GSKA1|SCHEMBL14247403|BCP28055|EX-A5297|AKOS037643421|ZINC144874408|AC-36732|AS-16345|HY-125118|CS-0089366|A900427|5-(2-Amino-1-(4-morpholinophenyl)-1H-benzimidazol-6-yl)-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide|E4S |
| Molecular Weight | 574.63 |
| Molecular Formula | C29H27FN6O4S |
| Canonical SMILES | COC1=C(C=C(C=N1)C2=CC3=C(C=C2)N=C(N3C4=CC=C(C=C4)N5CCOCC5)N)S(=O)(=O)NC6=CC=CC=C6F |
| Purity | ≥98% |
| Solubility | DMSO: 2 mg/ml |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 959 |
| Exact Mass | 574.17985270 |
| Target | PI4K; HCV |
| XLogP3-AA | 4 |
